NASDAQ · CLDX
Healthcare · Biotechnology
$38.10
Down-$0.68 (-1.75%)
Updated Sep 11, 2026, 8:39 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CLDX closed at $38.10 after 20 trading sessions, down 10.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $38.78 | $38.86 | $37.75 | $38.10 | 948.91K |
| Sep 9, 2026 | $38.95 | $40.035 | $38.67 | $38.78 | 588.42K |
| Sep 8, 2026 | $38.78 | $39.865 | $38.50 | $39.12 | 834.31K |
| Sep 4, 2026 | $38.96 | $39.81 | $38.902 | $39.68 | 414.53K |
| Sep 3, 2026 | $39.50 | $39.885 | $38.95 | $39.37 | 418K |
| Sep 2, 2026 | $39.43 | $40.55 | $39.01 | $39.48 | 476.59K |
| Sep 1, 2026 | $39.13 | $39.895 | $38.94 | $39.24 | 542.48K |
| Aug 31, 2026 | $38.86 | $39.84 | $38.74 | $39.63 | 696.91K |
| Aug 28, 2026 | $40.33 | $40.57 | $39.04 | $39.12 | 424.94K |
| Aug 27, 2026 | $40.44 | $40.995 | $40.02 | $40.46 | 450.01K |
| Aug 26, 2026 | $41.18 | $42.12 | $40.06 | $40.57 | 540.67K |
| Aug 25, 2026 | $41.02 | $41.9199 | $40.63 | $41.22 | 550.92K |
| Aug 24, 2026 | $40.16 | $40.98 | $39.53 | $40.57 | 416.89K |
| Aug 21, 2026 | $40.38 | $41.2399 | $40.12 | $40.38 | 837.69K |
| Aug 20, 2026 | $41.40 | $42.00 | $39.45 | $39.94 | 1M |
| Aug 19, 2026 | $42.10 | $43.20 | $41.325 | $41.70 | 1.39M |
| Aug 18, 2026 | $41.29 | $42.3601 | $41.03 | $41.79 | 998.96K |
| Aug 17, 2026 | $41.54 | $42.805 | $41.07 | $41.92 | 629.8K |
| Aug 14, 2026 | $42.23 | $42.345 | $40.88 | $41.95 | 849.36K |
| Aug 13, 2026 | $45.13 | $45.13 | $42.56 | $42.61 | 670.93K |
The latest Smart Investors Daily articles mentioning CLDX.
CLDX research
Company profile and research snapshot.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Morgan Stanley | Overweight | — |
| Aug 7, 2026 | Barclays | Overweight | — |
| Jul 29, 2026 | Wells Fargo | Overweight | — |
| Jul 22, 2026 | Morgan Stanley | Overweight | — |
| Jul 22, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
Benzinga · Aug 7, 2026
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
ChartMill · Aug 6, 2026
Celldex Q2 EPS beat revenue miss; barzolvolimab Ph3 data due 2026, prurigo nodularis discontinued. Cash $717.6M.
Benzinga · Aug 6, 2026
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLDX.
